We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Antabio SAS announced today that it has been awarded up to $8.9 million non-dilutive funding from CARB-X, the world's largest public-private partnership devoted to antibacterial R&D.